Dermaplus Inc. was formed in May 2004 to benefit from patents and related technology developed by Burt Ensley, the Chairman and Chief Executive Officer. Dr. Ensley's technology and know-how result from rapid progress in the fields of genomics, the study of the structure and function of genetic material and proteomics, the systematic analysis of protein expression in healthy and diseased tissue. These scientific tools can be used to design entirely unique products with enhanced performance.
- Burt D. Ensley Director and CEO
- Lorenzo A. DeLuca Director
- Amy Diamond Director
BURT D ENSLEY has been a Director of the Company since its inception. From 2000 to the present, Dr. Ensley has served as the VP of Research and President of NuCycle Therapy, a subsidiary of Integrated BioPharma, a publicly traded (INB) nutraceutical Company. From 1993 through its sale in 2000, Dr. Ensley was President, Chief Executive Officer and Director of Phytotech, Inc., a phytoremediation company. Previously, he served as Director of Advanced Technology at Envirogen, Inc., a microbial-based bioremediation company and headed the Specialty Chemicals Group at Amgen, Inc. Dr. Ensley received a B.S. and M.S. in Biology from the University of New Mexico in 1974 and 1976 and a Ph.D. in Microbiology from the University of Georgia in 1979. Dr. Ensley has served on the National Science Foundation’s BIO Directorate Advisory Board and as a Fellow of the American Academy of Microbiology since 1966.
LORENZO A. DELUCA
has served as a Director since April 2004. Mr. DeLuca is the President
of Paxton Ventures Corp., a venture capital and consulting firm specializing
in emerging growth companies. In connection with Paxton’s portfolio
investments, Mr. DeLuca has served as officer or director of Action Industries
Inc., General Vision Services, Inc., Bio-Reference Laboratories and Merchants
Advantage.com. Mr. DeLuca is an attorney admitted to practice in the State
of New York and was a founding member of Zervas & DeLuca. Mr. DeLuca
received a BA degree from Rutgers College and a J.D. degree from New York
Law School.
AMY DIAMOND has served as a Director since April 2004. Ms. Diamond is the founder of Deep River Capital and a Managing Director of Triumph Securities. Prior to this she was Managing Director of Chatsworth Securities, LLC and Director of Nolan Securities. She was an owner and Board member of Glemby International, an international personal care services company with 1300 stores worldwide and was responsible for successfully completing the sale of the Company. Ms. Diamond’s career includes corporate finance experience with Lazard Freres and Cornerstone Asset Management. She has substantial experience in the media business having spent several years with the American Broadcasting Company. She has a BA in Psychology from New York University and an MBA in Finance from New York University Graduate School of Business. Ms. Diamond serves on the board of Shakespeare & Company, based in Lenox, Massachusetts.